Showing 4571-4580 of 8697 results for "".
- With New Roles for Company Vets, Crown Doubles Down on Commitment to Aestheticshttps://practicaldermatology.com/news/with-new-roles-for-industry-vets-crown-doubles-down-on-commitment-to-aesthetics/2461242/Joe Proctor and Michael McKenna are stepping into new roles at Crown Laboratories. Joe Proctor will transition from General Manager, Aesthetics into the Head of Innovation and Corporate Development for Crown Aesthetics. Mr. Proctor is the founder of Crown
- Dermatologists Rule for Cosmetic Procedures and Skin Care Decisionshttps://practicaldermatology.com/news/dermatologists-rule-for-cosmetic-procedures-and-skin-care-decisions/2461241/Dermatologists rank as the number one influencer among 16 factors that impact consumers’ decisions to have a cosmetic procedure, according to the 2021
- New Crystal Ball Predictions Released by Allergan Aestheticshttps://practicaldermatology.com/news/new-crystal-ball-predictions-released-by-allergan-aesthetics/2461238/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- ProofPilot Wants You to Submit Research Ideas on Issues Concerning BIPOC Communitieshttps://practicaldermatology.com/news/proofpilot-wants-you-to-submit-research-ideas-on-issues-concerning-bipoc-communities/2461237/ProofPilot, a Software as a Service (SaaS) clinical trial research platform, is rolling out its first ever Open Invitation for Research, in partnership with the nonprofit organization
- Vial Dermatology CRO adds Dr. Jonathan Zung to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-dermatology-cro-adds-dr-jonathan-zung-to-scientific-advisory-boar/2461236/The Vial Dermatology CRO welcomed Jonathan Zung, PhD, as the newest addition to the Vial Scientific Advisory Board. Dr. Zung will support the Vial CRO team and their sponsors to further advance the field of dermatology clinical researc
- CeraVe and Dr. Amy Brodsky to Observe Sun Safety Day at Wrigley Fieldhttps://practicaldermatology.com/news/cerave-and-dr-amy-brodsky-to-observe-sun-safety-day-at-wrigley-field/2461235/CeraVe is sponsoring Sun Safety Day at Wrigley Field this weekend with event founder, Chicago-based board-certified dermatologist, Amy Brodsky, MD. Melanoma diagnosis in young adults is up 253% in the last 40 years. Sun damage in childhood is one of the leading factors o
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b
- Calling All Dermatologists: The Sun Heroes Initiative Wants You to Become a Herohttps://practicaldermatology.com/news/calling-all-dermatologists-the-sun-heroes-initiative-wants-you-to-help-bring-sun-safety-programs-to-elementary-schools/2461232/CeraVe and L'Oreal Dermatological Beauty brand La Roche-Posay are teaming up with dermatologist Amy Brodsky, MD to bring sun safety programs to elementary schools around the country. Sun Heroes is an educational program that equips healthcare professionals with
- Higher Fish Consumption Linked to Melanoma Riskhttps://practicaldermatology.com/news/higher-fish-consumption-linked-to-melanoma-risk/2461229/Eating higher levels of fish, including tuna and non-fried fish, may increase melanoma risk, according to a large study of US adults published in Cancer Causes & Control. When compared to those whose median daily fish intake was 3.2 grams, the risk of malignant melanom
- FDA Approves Dupixent for Children 6 Months to 5 Years with Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-dupixent-for-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis/2461224/The FDA has approved Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab) for children aged 6 months to 5 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Regu